Showing 1391-1400 of 5603 results for "".
Tardive Dyskinesia, Decoded: From Subtle Signs to Personalized VMAT2 Therapy
https://reachmd.com/programs/cme/tardive-dyskinesia-decoded-from-subtle-signs-to-personalized-vmat2-therapy/54692/Improve your diagnostic and screening skills for tardive dyskinesia and learn about the important role of VMAT2 inhibitors in the management of this disorder.Chairperson’s Perspective: TROP2-Targeted ADCs in TNBC and HR+ mBC
https://reachmd.com/programs/cme/chairpersons-perspective-trop2-targeted-adcs-in-tnbc-and-hr-mbc/54128/This activity reviews clinical evidence and interdisciplinary strategies for integrating TROP2-targeted ADCs in TNBC and HR+ metastatic breast cancer care.Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
https://reachmd.com/programs/cme/stuck-on-antihistamines-for-managing-patients-with-ckd-ap-time-to-reconsider/37607/Apply clinical practice guideline recommendations in managing patients with chronic kidney disease-associated pruritus (CKD-aP).The Ambulatory HFrEF Blind Spot: Proactively Reducing CV Mortality Risk Despite Optimized GDMT
https://reachmd.com/programs/cme/the-ambulatory-hfref-blind-spot-proactively-reducing-cv-mortality-risk-despite-optimized-gdmt/48810/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
https://reachmd.com/programs/cme/breaking-down-the-benchmarks-pivotal-data-on-first-line-cdk46-inhibitors/39798/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Spotlight on Latin America: Closing the Gap
https://reachmd.com/programs/cme/spotlight-on-latin-america-closing-the-gap/39809/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC
https://reachmd.com/programs/cme/rethinking-the-therapeutic-targeting-of-b7-h3-in-es-sclc/37876/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Visible Benefit of Compression for Leukocytoclastic Vasculitis
https://reachmd.com/programs/practical-dermatology/visible-benefit-of-compression-for-leukocytoclastic-vasculitis/24212/The use of compression stockings has been suggested in the management of leukocytoclastic vasculitis (LCV), however there are a lack of studies in the literature that provide evidence of the benefit of compression therapy in the treatment of LCV.1,2 Here we present a case that visually demonstratesA Clinician's Guide to the ACIP Travel Vaccination Recommendations
https://reachmd.com/programs/vaccination/a-clinicians-guide-to-the-acip-travel-vaccination-recommendations/26483/Get ready to integrate the latest ACIP updates into practice to improve patient care and public health outcomes with this essential recap.I Just Received an Offer from a Private Equity Firm. What Should I Do Now?
https://reachmd.com/topics/practice-development/i-just-received-an-offer-from-a-private-equity-firm-what-should-i-do-now/35206/Why you need a knowledgeable transaction advisor when considering a private equity deal.